4.7 Article

Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer's disease

Journal

SCIENTIFIC REPORTS
Volume 7, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41598-017-06624-y

Keywords

-

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  2. DOD ADNI (Department of Defense award) [W81XWH-12-2-0012]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. AbbVie
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Araclon Biotech
  9. BioClinica, Inc.
  10. Biogen
  11. Bristol-Myers Squibb Company
  12. CereSpir, Inc.
  13. Eisai Inc.
  14. Elan Pharmaceuticals, Inc.
  15. Eli Lilly and Company
  16. EuroImmun
  17. F. Hoffmann-La Roche Ltd
  18. Genentech, Inc.
  19. Fujirebio
  20. GE Healthcare
  21. IXICO Ltd.
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  23. Johnson & Johnson Pharmaceutical Research & Development LLC.
  24. Lumosity
  25. Lundbeck
  26. Merck Co., Inc.
  27. Meso Scale Diagnostics, LLC.
  28. NeuroRx Research
  29. Neurotrack Technologies
  30. Novartis Pharmaceuticals Corporation
  31. Pfizer Inc.
  32. Piramal Imaging
  33. Servier
  34. Takeda Pharmaceutical Company
  35. Transition Therapeutics
  36. Canadian Institutes of Health Research
  37. European Commission's [604102]
  38. MAESTRA project [612944]
  39. InnoMol project [316289]
  40. Croatian Science Foundation (Machine Learning Algorithms for Insightful Analysis of Complex Data Structures) [9623]
  41. Slovenian Research Agency (program Knowledge Technologies and project Development and Applications of New Semantic Data Mining Methods in Life Sciences)
  42. Cure Alzheimer's Fund
  43. Karen L Wrenn Family Trust
  44. Wrenn Scholar's Program
  45. NIH [1RF1AG048080-01, 5R37MH060009]

Ask authors/readers for more resources

The heterogeneity of Alzheimer's disease contributes to the high failure rate of prior clinical trials. We analyzed 5-year longitudinal outcomes and biomarker data from 562 subjects with mild cognitive impairment (MCI) from two national studies (ADNI) using a novel multilayer clustering algorithm. The algorithm identified homogenous clusters of MCI subjects with markedly different prognostic cognitive trajectories. A cluster of 240 rapid decliners had 2-fold greater atrophy and progressed to dementia at almost 5 times the rate of a cluster of 184 slow decliners. A classifier for identifying rapid decliners in one study showed high sensitivity and specificity in the second study. Characterizing subgroups of at risk subjects, with diverse prognostic outcomes, may provide novel mechanistic insights and facilitate clinical trials of drugs to delay the onset of AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available